Nevirapine contraindications

Nevirapine
VIRAMUNE^® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sophia Saad, Associate Editor – WikiDoc [2]

Contraindications

Hepatic Impairment

VIRAMUNE XR is contraindicated in patients with moderate or severe (Child-Pugh Class B or C, respectively) hepatic impairment [see Warnings and Precautions (5.1) and Use in Specific Populations (8.7)].

Post-Exposure Prophylaxis

VIRAMUNE XR is contraindicated for use as part of occupational and non-occupational post-exposure prophylaxis (PEP) regimens [see Warnings and Precautions (5.1)].^[1]

References

↑ “VIRAMUNE (NEVIRAPINE) TABLET, EXTENDED RELEASE [BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.]”. Retrieved 10 January 2014.

Adapted from the FDA Package Insert.

[dailymed.nlm.nih.gov-1] “VIRAMUNE (NEVIRAPINE) TABLET, EXTENDED RELEASE [BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.]”. Retrieved 10 January 2014.

[1]

Nevirapine contraindications

Contraindications

Hepatic Impairment

Post-Exposure Prophylaxis

References

Looking for the patient version?